G
GNOMX develops anAI‑powered epigenetic diagnostic platform that identifies infectious pathogens and predicts clinical outcomes such as sepsis patient readmission. The technology integrates epigenomic biomarkers with machine‑learning models to deliver actionable insights for hospitals, labs, and public‑health agencies. Revenue is generated through licensing of the diagnostic software, per‑test fees, and government contracts such as the BARDA DRIVe award.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- GNOMX provides an epigenetic and AI-powered diagnostic platform for infectious diseases. The system predicts patient outcomes such as sepsis readmission risk using advanced biomarker analysis. It supports healthcare providers in early detection and targeted intervention.